Nutriband Inc
Research Nutriband Inc (NTRB) on Bullrun: market cap USD 58.71M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTRB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 58.71M
- Financial periodFY2026
- RevenueUSD 2.04M
- Revenue growth-4.8%
- Net income-USD 8.23M
- Free cash flow-USD 5.14M
- Gross margin27.8%
Valuation Snapshot
latest market cap is USD 58.71M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 2.04M | -USD 8.23M | -USD 5.14M | 27.8% | -2.58 | USD 4.57M | USD 232.71K | USD 6.68M |
| FY2025 | USD 2.14M | -USD 10.48M | -USD 4.72M | 34.7% | -0.99 | USD 4.31M | USD 258.03K | USD 6.43M |
| FY2024 | USD 2.09M | -USD 5.49M | -USD 3.58M | 41.3% | -0.69 | USD 492.94K | USD 2.00M | USD 6.44M |
| FY2023 | USD 2.08M | -USD 4.48M | -USD 3.07M | 36.1% | -0.53 | USD 1.99M | USD 2.25M | USD 8.57M |
| FY2022 | USD 1.42M | -USD 6.18M | -USD 2.89M | 39.0% | -0.8 | USD 4.89M | USD 199.80K | USD 11.86M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 58.71M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 55.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 52.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 19.63M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 28.28M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 78.36M | n/a | n/a | n/a |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nutriband Inc's market cap?
Nutriband Inc's market capitalization is USD 58.71M.
What does Nutriband Inc do?
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.